CARGO Therapeutics, Inc. financial data

Symbol
CRGX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
835 Industrial Road, Suite 400, San Carlos, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.17K %
Debt-to-equity 17.4 %
Return On Equity -53.5 % -145%
Return On Assets -40.8 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 45.9M shares
Common Stock, Shares, Outstanding 41.2M shares +3674%
Common Stock, Value, Issued 46K USD
Weighted Average Number of Shares Outstanding, Basic 43.3M shares +6348%
Weighted Average Number of Shares Outstanding, Diluted 43.3M shares +6348%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 117M USD +169%
General and Administrative Expense 36.5M USD +207%
Operating Income (Loss) -154M USD -177%
Net Income (Loss) Attributable to Parent -148M USD -161%
Earnings Per Share, Basic 29.5 USD/shares +96.2%
Earnings Per Share, Diluted 29.5 USD/shares +96.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 154M USD +262%
Marketable Securities, Current 290M USD
Assets, Current 448M USD
Property, Plant and Equipment, Net 11.8M USD
Operating Lease, Right-of-Use Asset 25.1M USD
Other Assets, Noncurrent 4.38M USD
Assets 490M USD
Accounts Payable, Current 7.01M USD
Employee-related Liabilities, Current 3.47M USD
Accrued Liabilities, Current 5.64M USD
Liabilities, Current 26.4M USD
Operating Lease, Liability, Noncurrent 27.5M USD
Other Liabilities, Noncurrent 225K USD -10%
Liabilities 53.9M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -323K USD
Retained Earnings (Accumulated Deficit) -225M USD
Stockholders' Equity Attributable to Parent 436M USD
Liabilities and Equity 490M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -30.1M USD -114%
Net Cash Provided by (Used in) Financing Activities -104K USD -100%
Net Cash Provided by (Used in) Investing Activities -294M USD -47389%
Common Stock, Shares Authorized 500M shares +1624%
Common Stock, Shares, Issued 41.2M shares +3674%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -324M USD -670%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 154M USD +264%
Deferred Tax Assets, Valuation Allowance 30.4M USD +179%
Deferred Tax Assets, Gross 37M USD +226%
Operating Lease, Liability 28.1M USD
Depreciation 2.13M USD +100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -44.4M USD -149%
Lessee, Operating Lease, Liability, to be Paid 45.8M USD
Property, Plant and Equipment, Gross 14.9M USD
Operating Lease, Liability, Current 649K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 7.22M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 4.68M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 17.6M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 7.44M USD
Deferred Tax Assets, Operating Loss Carryforwards 2.28M USD +83%
Unrecognized Tax Benefits 1.23M USD +41.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 7.44M USD
Operating Lease, Payments 1.29M USD +185%
Additional Paid in Capital 662M USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares